Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine

Anastasia, Luigi; Pasqui, Gabriele; Venerando, Bruno; Tettamanti, Guido

doi:10.1038/cdd.2010.14

Cited by 42 publications

(27 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At our present level of knowledge, failure of full and uniform reprogramming in iPSCs might result in resistance to differentiation and to an increase in the risk of teratoma formation, with poor control over self-renewal of pluripotency after transplantation. In the last few years, several new non-genetic reprogramming methods have been proposed, such as chemically induced pluripotent cells (Anastasia et al, 2010), which can be obtained with recombinant proteins or with small synthetic molecules; these might represent a simpler and safer approach. This will not only be useful for the improvement of iPSC technology, but it will also contribute to better characterize the signalling pathways that operate in iPSC induction, which will itself open new avenues for mechanistic dissection of these reprogramming processes.…”

Section: Concluding Future Remarksmentioning

confidence: 99%

Reprogramming cell fate to pluripotency: the decision-making signalling pathways

Sanges¹,

Cosma²

2010

Int. J. Dev. Biol.

View full text Add to dashboard Cite

Pluripotency can be defined as the ability of individual cells to initiate all of the lineages of the mature organism in response to signals from the environment. It has long been assumed that during development, pluripotency is progressively and irreversibly lost through a mechanism that requires strict coordination of the signalling pathways involved in cell proliferation, differentiation and migration. However, recent breakthroughs have highlighted evidence that terminally differentiated cells can be reprogrammed into pluripotent stem cells, prompting a re-evaluation of the reversibility of cell differentiation. Generations of pluripotent cells can arise from somatic cells following ectopic expression of specific transcription factors; however, these factors might well not be the unique essential reprogramming factors. Furthermore, they can be the end-point targets of signalling pathways. Indeed, recent evidence shows that modulation of the Wnt/    -catenin, MAPK/ERK, TGF-     or PI3K/Akt signalling pathways strikingly enhances somatic-cell reprogramming. Nevertheless, we still know relatively little about the underlying mechanisms by which somatic cells de-differentiate to pluripotency. In this review, we provide an overview of the signalling pathways promoting the re-acquisition and maintenance of pluripotency and we discuss the possible mechanisms underlying nuclear reprogramming.

show abstract

Section: Concluding Future Remarksmentioning

confidence: 99%

Reprogramming cell fate to pluripotency: the decision-making signalling pathways

Sanges¹,

Cosma²

2010

Int. J. Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Later, some reports showed that reversine had a role in regeneration (Anastasia et al 2006;Kim et al 2007;Saraiya et al 2010;Anastasia et al 2010;Jung and Williams 2011). Moreover, a recent report showed that reversine had anti-tumor capabilities such as for a myeloma cell line (McMillin et al 2010), and demonstrated that reversine could suppress the expression of cell cycle related proteins Aurora kinase A (Aur-A) and Aurora kinase B (Aur-B), and also could suppress enzymes involved in cell growth signaling, such as JAK2 and SRC (McMillin et al 2010;Hua et al 2012;Shan et al 2007;Jemaà et al 2012;Kuo et al 2012;Hsieh et al 2007).…”

Section: Introductionmentioning

confidence: 99%

Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo

et al. 2013

View full text Add to dashboard Cite

A recent report showed that reversine treatment could induce murine myoblasts dedifferentiation into multipotent progenitor cells and inhibit proliferation of some tumors, and other reports showed that apoptosis of lung adenocarcinoma cells could be induced by aspirin. The aim of the present study was to evaluate the synergistic antitumor effects of reversine and aspirin on cervical cancer. The inhibition rate of reversine and aspirin on cervical cancer cell lines' (HeLa and U14) was determined by MTT method, cell cycle of HeLa and U14 cells was analyzed by FACS, mitochondrial membrane potential of HeLa and U14 was detected using a JC-1 kit. HeLa and U14 colony formation was analyzed by soft agar colony formation assay. The expression of caspase-3, Bcl-2/Bax, cyclin D1 and p21 was detected by qRT-PCR and Western Blotting. Moreover, tumor weight and tumor volume was assessed using a murine model of cervical cancer with U14 cells subcutaneously (s.c.) administered into the neck, separately or combined with drug administration via the intraperitoneal (i.p.) route. The inhibition rate of cells in the combination group (10 lmol/L reversine, 10 mmol/ L aspirin) increased significantly in comparison to that when the drugs were used alone (P \ 0.05); moreover, this combination could synergistically inhibit the proliferation of five cervical cancer cell lines (HeLa, U14, Siha, Caski and C33A). In the therapeutic mouse model, tumor weight and tumor volume of cervical cancer bearing mice was more reduced when compared with the control agents (P \ 0.05) in tumor-bearing mice. The combination of reversine and aspirin exerts synergistic growth inhibition and apoptosis induction on cervical cancers cells.

show abstract

“…On the one hand, unexpected inconsistencies might be related with several strategies of recruitment and maturation of stem cells and using of different types of stem cells. On the other hand, DM patient populations are not uniform that negatively associates with results of stem cells transplantation [12,13] . The purpose of the review was to summarize and analyse data for knowledge and prospects for future researches in the field of regenerative therapy in DM patients.…”

Section: Introductionmentioning

confidence: 99%

Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives

Berezin¹

2014

WJD

View full text Add to dashboard Cite

Diabetes mellitus (DM) is the most prevailing disease with progressive incidence worldwide. Despite contemporary treatment type one DM and type two DM are frequently associated with long-term major microvascular and macrovascular complications. Currently restoration of failing β-cell function, regulation of metabolic processes with stem cell transplantation is discussed as complements to contemporary DM therapy regimens. The present review is considered paradigm of the regenerative care and the possibly effects of cell therapy in DM. Reprogramming stem cells, bone marrowderived mononuclear cells; lineage-specified progenitor cells are considered for regenerative strategy in DM. Finally, perspective component of stem cell replacement in DM is discussed.

show abstract

Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine

Cited by 42 publications

References 99 publications

Reprogramming cell fate to pluripotency: the decision-making signalling pathways

Reprogramming cell fate to pluripotency: the decision-making signalling pathways

Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo

Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives

Contact Info

Product

Resources

About